PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmbrepsJournal HomeArchivesInstruction to AuthorsOnline SubmissionBMB Reports Online
 
BMB Rep. 2016; 49(11): 617–622.
Published online 2016 November 30. doi:  10.5483/BMBRep.2016.49.11.117
PMCID: PMC5346322

Protective effects of Tat-NQO1 against oxidative stress-induced HT-22 cell damage, and ischemic injury in animals

Abstract

Oxidative stress is closely associated with various diseases and is considered to be a major factor in ischemia. NAD(P)H: quinone oxidoreductase 1 (NQO1) protein is a known antioxidant protein that plays a protective role in various cells against oxidative stress. We therefore investigated the effects of cell permeable Tat-NQO1 protein on hippocampal HT-22 cells, and in an animal ischemia model. The Tat-NQO1 protein transduced into HT-22 cells, and significantly inhibited against hydrogen peroxide (H2O2)-induced cell death and cellular toxicities. Tat-NQO1 protein inhibited the Akt and mitogen activated protein kinases (MAPK) activation as well as caspase-3 expression levels, in H2O2 exposed HT-22 cells. Moreover, Tat-NQO1 protein transduced into the CA1 region of the hippocampus of the animal brain and drastically protected against ischemic injury. Our results indicate that Tat-NQO1 protein exerts protection against neuronal cell death induced by oxidative stress, suggesting that Tat-NQO1 protein may potentially provide a therapeutic agent for neuronal diseases.

Keywords: Akt/MAPK, Ischemia, Oxidative stress, Protein therapy, Tat-NQO1

INTRODUCTION

NAD(P)H: quinone oxidoreductase 1 (NQO1), a cytosolic FAD-dependent flavoprotein, catalyzes the reduction of quinines, quinoneimines, and nitroaromatics and regulates the intracellular ratio of NAD and NADH in several cells. Human NQO1 protein is highly expressed in numerous cells including epithelial cells, vascular endothelium, and adipocyte cells, where it is localized in the cytosol and the nucleus (14). Several studies have demonstrated that NQO1 is a multifunctional protein, and shows an antioxidant effect by decreasing the intracellular reactive oxygen species (ROS) levels and various toxicities (3, 4). Other studies have shown that NQO1 protein plays a key role in various tumors, including breast, hepatoma, and pancreas, by exerting its effects on tumor growth inhibition, suggesting NQO1 protein as a potential therapeutic agent for cancer (5, 6). However, the protective function and precise mechanism of NQO1 protein in ischemia are still unclear.

Oxidative stress induced by reactive oxygen species (ROS) is strongly implicated in brain diseases, including ischemia. Excessive oxidative stress alters the structure of proteins, lipids, and DNA, as well as cellular homeostasis signaling pathways, finally leading to cell death (7, 8). Antioxidant proteins are known to play a critical role in various diseases. Recent studies have shown that ischemia reperfusion-induced oxidative stress plays an important role in the pathogenesis of cerebral ischemia, and antioxidants are in use for the treatment of ischemia (9, 10).

Protein transduction domains (PTDs) deliver various molecules into cells, and are widely used as therapeutic strategies for various diseases including neuronal disorders (11, 12). In previous studies, we have demonstrated that antioxidant PTD fusion proteins transduce into various cells, and markedly inhibit cell damage induced by oxidative stress (1317). In this study, we investigated the effects of Tat-NQO1 protein against oxidative stress-induced HT-22 cell death, and ischemic injury in an animal model.

RESULTS AND DISCUSSION

Transduction of purified Tat-NQO1 protein into HT-22 cells

NQO1 protein is a multifunctional protein which plays a detoxifying role against various stimuli. Recent studies have revealed that NQO1 protein prevents acute renal damage induced by ischemia-reperfusion injury (IRI), via inhibition of renal oxidative stress (18, 19). Therefore, we constructed a cell permeable Tat-NQO1 protein to study whether Tat-NQO1 protein has protective effects against oxidative stress-induced hippocampal neuronal cell damage. As shown in Fig. 1A, the Tat-NQO1 protein expression vector contained a NQO1 cDNA, Tat peptide, and six histidine residues at the amino-terminus. However, the control NQO1 protein expression vector contained no Tat peptides. After the Tat-NQO1 or control NQO1 proteins were overexpressed with IPTG in E. coli, the proteins were purified using a Ni-NTA His affinity column and PD-10 column chromatography. Purified Tat-NQO1 and control NQO1 proteins were analyzed by SDS-PAGE and Western blot analysis using an anti-histidine antibody (Fig. 1A).

Fig. 1
Purification and transduction of Tat-NQO1 protein into HT-22 cells. Purification of Tat-NQO1 protein. Purified proteins were analyzed by 12% SDS-PAGE and subjected to Western blot analysis with an anti-histidine antibody (A). Transduction of Tat-NQO1 ...

To determine whether Tat-NQO1 proteins transduce into HT-22 cells, the cells were treated with various quantities of Tat-NQO1 protein (0.5–3 μM) for 2 h, or with Tat-NQO1 protein (3 μM) for various times (10–120 min). The transduced proteins were then measured by Western blotting analysis. Figs. 1B and 1C show that Tat-NQO1 protein transduced into the cells in dose- and time-dependent manners. However, control NQO1 protein did not transduce under the same experimental conditions. In addition, we observed that transduced Tat-NQO1 protein levels significantly persisted for up to 60 h in the cells (Fig. 1D). These results indicate that constructed and purified Tat-NQO1 protein successfully transduced into HT-22 cells, where it persisted for up to 60 h.

Since protein transduction domains (PTDs) can successfully deliver numerous proteins into cells or tissues, PTD fusion proteins are commonly used to better understand the novel functions of various proteins. Many studies have demonstrated that PTD fusion proteins, including Tat peptide, can be used as therapeutic proteins in various diseases (11, 1217).

Effects of transduced Tat-NQO1 protein against H2O2-induced cell death

We performed fluorescence analysis to examine the distribution of transduced Tat-NQO1 protein in HT-22 cells. In Tat-NQO1 protein treated cells, fluorescence signals were detected in both the nucleus and cytosol of HT-22 cells. In contrast, fluorescence signals were undetected in cells treated with control NQO1 protein (Fig. 2A).

Fig. 2
Effects of transduced Tat-NQO1 protein against H2O2-induced cellular toxicity. Cellular distribution of transduced Tat-NQO1 protein in HT-22 cells. Cells were treated with Tat-NQO1 (3 μM) protein for 2 h, and the cellular distribution of Tat-NQO1 ...

ROS are closely associated with various diseases, including ischemia. Ischemic injury induces neuronal cell death by production of excessive ROS, which leads to destruction of DNA, protein, and lipids, and ultimately cell death (7, 20, 21). To confirm whether transduced Tat-NQO1 protein has protective effects against H2O2-induced HT-22 cell death, HT-22 cells were treated with Tat-NQO1 protein (3 μM) and control NQO1 protein (3 μM) for 2 h, followed by H2O2 (1 mM) treatment for 10 h. Vehicle control group cells were treated with only H2O2 (1 mM) for 10 h. Cell survival increased up to 67% in Tat-NQO1 protein treated cells, whereas control NQO1 protein showed the same patterns as the H2O2 only treated cells (Fig. 2B).

Next, using fluorescence staining, we determined the effects of Tat-NQO1 protein against H2O2-induced intracellular ROS generation and DNA fragmentation in HT-22 cells. Fluorescence signal levels were markedly increased in H2O2 exposed cells compared to control cells, and the fluorescence signals in control NQO1 protein treated cells were similar to the H2O2 exposed cells (Fig. 2C and 2D). However, fluorescence signals were markedly reduced in Tat-NQO1 protein treated cells. These results indicate that transduced Tat-NQO1 protein inhibits oxidative stress-induced cell death and has as antioxidant function by reducing ROS generation and DNA damage. In agreement with our results, other studies have demonstrated that NQO1 protein plays an antioxidant protein role, inhibiting salt- or cisplatin-induced ROS production and renal damage in ACHN cells, human kidney cell line, and in a NQO1−/− mice model (2224). Another study reported that pre-treatment of β-lapachone (β-LAP), which is known as an activator of NQO1, showed increase in the NQO1 activity and inhibition of total ROS levels, H2O2, superoxide anion radical, lipid peroxidation, and DNA damage in high salt-induced kidney of rats (23). Therefore, our results are consistent with results wherein NQO1 has an anti-oxidant effect, and protects the cells and tissues against oxidative damage.

Effects of Tat-NQO1 protein on H2O2-induced activation of Akt, MAPK and caspase-3

Several studies have shown that Akt and MAPK signaling pathways are associated with ROS, get activated by oxidative stress, and eventually lead to cell death (25, 26). We examined the effects of Tat-NQO1 protein against H2O2-induced Akt and MAPK activation in HT-22 cells. Tat-NQO1 protein markedly reduced the activation of Akt and MAPK levels in the H2O2 exposed HT-22 cells, whereas control NQO1 protein did not demonstrate similar effects (Fig. 3A and 3B). Consistent with our results, recent studies have demonstrated that β-LAP inhibited H2O2 induced ROS production and cell death in rat primary astrocytes. Also, β-LAP increased antioxidant enzyme expression in rat primary astrocytes, and enhanced the cell survival via regulation of AMPK/PI3K-Nrf2/ARE signaling as well as activation of Akt and MAPK signaling pathways (27).

Fig. 3
Effect of Tat-NQO1 protein on the activation of Akt, MAPK, and caspase-3 in HT-22 cells. The cells were treated with Tat-NQO1 protein and then exposed to H2O2 as described in the “Materials and methods” section. The activation of Akt, ...

It is well known that apoptotic triggers can activate the mitochondrial pathway and active caspase cascades, which in turn activate caspase-3, finally leading to cellular apoptosis. The balance of apoptosis related factors is important for cell homeostasis (28, 29). We examined the effects of Tat-NQO1 protein against H2O2-induced changes in caspase-3 and cleaved caspase-3 expression levels in HT-22 cells. We observed that Tat-NQO1 protein increased the caspase-3 expression levels in the H2O2 exposed HT-22 cells, whereas it had an inverse effect on the expression levels of cleaved caspase-3. Control NQO1 protein did not change the protein expression levels under the same conditions (Fig. 3C). These results indicate that Tat-NQO1 protein promotes cell survival in H2O2-induced HT-22 cells via regulation of Akt and MAPK activation as well as apoptosis signaling.

Effects of Tat-NQO1 protein against ischemic insults

To determine the effects of transduced Tat-NQO1 protein against ischemic insults, we performed immunostaining using an anti-histidine, NeuN, and DAPI antibody. Fig. 4A shows that Histidine- and NeuN-immunoreactive cells were markedly increased in the hippocampal CA1 region in the Tat-NQO1 protein treated group compared to the vehicle treated group. In contrast, the control NQO1 protein treated group showed a similar pattern to the vehicle treated group. These results indicate that Tat-NQO1 protein transduced into the hippocampal CA1 region, successfully crossing the blood-brain barrier (BBB), where it protected against hippocampal neuronal cell death resulting from ischemic insults.

Fig. 4
Effects of transduced Tat-NQO1 protein in an animal model of ischemia. Gerbils were treated with a single injection of Tat-NQO1 protein (2 mg/kg) before ischemia-reperfusion, and sacrificed after 7 days. Transduced Tat-NQO1 protein was analyzed by immunostaining, ...

We also performed cresyl violet (CV) and Fluoro-Jade B (F-JB) staining to examine hippocampal neuronal cell death resulting from ischemic insults (Fig. 4B). CV-immunoreactive cells were significantly increased in the hippocampal CA1 region in the Tat-NQO1 protein treated group, whereas there was no significant differentiation of CV-immunoreactive cells in the control NQO1 protein treated group as compared to the vehicle group. In the vehicle treated group, F-JB-immunoreactive cells were increased in the CA1 region compared to that in the sham control group. However, Tat-NQO1 protein treated groups had markedly reduced F-JB-immunoreactive cells in the CA1 region compared to the vehicle treated group. Further, we performed ionized calcium-binding adapter molecule 1 (Iba-1) and glial fibrillary acidic protein (GFAP) staining to examine the effects of Tat-NQO1 protein on the activation of astrocytes and microglia in the hippocampal CA1 region. As shown in Fig. 4B, Tat-NQO1 protein markedly reduced the levels of Iba-1 and GFAP-immunoreactive cells, whereas control NQO1 protein did not show the same effects. These results indicate that transduced Tat-NQO1 protein significantly protected against ischemic insults via inhibition of astrocyte and microglia activation.

The activation of astrocytes and microglia are highly associated with ischemic injury, and is increased in the hippocampus CA1 region in animal models of ischemia (30, 31). Several studies have demonstrated that NQO1 protein prevents acute renal damage induced by ischemia-reperfusion. Also, β-LAP prevented primary astrocyte damage caused by oxidative stress (19, 24, 27). In agreement with these results, we showed that Tat-NQO1 protein significantly inhibited the activation of astrocytes and microglia in an animal model of ischemia. However, further studies are needed to evaluate the role of Tat-NQO1 protein on ischemic injury, and clarify the precise mechanism behind this process.

To summarize, we have demonstrated that Tat-NQO1 protein are transduced into HT-22 cells, and the transduced protein significantly protected against oxidative stress-induced HT-22 cell death by inhibition of cellular toxicities and activation of Akt and MAPK. In addition, Tat-NQO1 protein exerts a protective effect against ischemic injury, suggesting that Tat-NQO1 protein may be a potential strategy for neuronal disorders, including ischemia.

MATERIALS AND METHODS

See supplementary information for this section.

Supplementary Information

ACKNOWLEDGEMENTS

This work was supported by a Priority Research Centers Program grant (NRF-2009-0093812) and Mid-Career Researcher Program grant (2016R1A2B4008356) through the National Research Foundation of Korea funded by the Ministry of Education, and Ministry of Science, ICT & Future Planning. This study was also supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (2015R1D1A3A01015668) in the Republic Korea.

REFERENCES

1. Vasiliou V, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum Genomics. 2006;2:329–335. doi: 10.1186/1479-7364-2-5-329. [PMC free article] [PubMed] [Cross Ref]
2. Winski SL, Koutalos Y, Bentley DL, Ross D. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res. 2002;62:1420–1424. [PubMed]
3. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116. doi: 10.1146/annurev.pharmtox.46.120604.141046. [PubMed] [Cross Ref]
4. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys. 2010;501:116–123. doi: 10.1016/j.abb.2010.03.019. [PMC free article] [PubMed] [Cross Ref]
5. Gayam SR, Venkatesan P, Sung YM, et al. An NAD(P)H:quinone oxidoreductase 1 (NQO1) enzyme responsive nanocarrier based on mesoporous silica nanoparticles for tumor targeted drug delivery in vitro and in vivo. Nanocacle. 2016;8:12307–12317. [PubMed]
6. Danason S, Ward TH, Butler J, Ranson M. DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev. 2004;30:437–449. doi: 10.1016/j.ctrv.2004.01.002. [PubMed] [Cross Ref]
7. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 2001;21:2–14. doi: 10.1097/00004647-200101000-00002. [PubMed] [Cross Ref]
8. Santos CXC, Anilkumar N, Zhang M, Brewer AC, Shah AM. Redox signaling in cardiac myocytes. Free Radic Biol Med. 2011;50:777–793. doi: 10.1016/j.freeradbiomed.2011.01.003. [PMC free article] [PubMed] [Cross Ref]
9. Crawford A, Fassett RG, Geraghty DP, et al. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene. 2012;501:89–103. doi: 10.1016/j.gene.2012.04.011. [PubMed] [Cross Ref]
10. Taveira M, Sousa C, Valentao P, Ferreres F, Teixeira JP, Andrade PB. Neuroprotective effect of steroid alalkaloids on glutamate-induced toxicity by preserving mitochondrial membrane potential and reducing oxidative stress. J Steroid Biochem Mol Biol. 2014;140:106–115. doi: 10.1016/j.jsbmb.2013.12.013. [PubMed] [Cross Ref]
11. Wadia JS, Dowdy SF. Protein transduction technology. Curr Opin Biotechnol. 2002;13:52–56. doi: 10.1016/S0958-1669(02)00284-7. [PubMed] [Cross Ref]
12. Ramsey JD, Flynn NH. Cell-penetrating peptides transport therapeutics into cells. Pharmacol Thera. 2015;154:78–86. doi: 10.1016/j.pharmthera.2015.07.003. [PubMed] [Cross Ref]
13. Shin MJ, Kim DW, Lee YP, et al. Tat-glyoxalase protein inhibits against ischemic neuronal cell damage and ameliorates ischemic injury. Free Radic Biol Med. 2014;67:195–210. doi: 10.1016/j.freeradbiomed.2013.10.815. [PubMed] [Cross Ref]
14. Jeong HJ, Yoo DY, Kim DW, et al. Neuroprotective effect of PEP-1-peroxiredoxin2 on CA1 region in the hippocampus against ischemic insult. Biochim Biophys Acta. 20141840:2321–2330. doi: 10.1016/j.bbagen.2014.03.003. [PubMed] [Cross Ref]
15. Kim MJ, Park M, Kim DW, et al. Transduced PEP-1-PON1 protein regulate microglial activation and dopaminergic neuronal death in a Parkinson’s model. Biomaterials. 2015;64:45–56. doi: 10.1016/j.biomaterials.2015.06.015. [PubMed] [Cross Ref]
16. Jo HS, Yeo HJ, Cha HJ, et al. Transduced Tat-DJ-1 protein inhibits cytokines-induced pancreatic RINm5F cell death. BMB Rep. 2016;49:297–302. doi: 10.5483/BMBRep.2016.49.5.058. [PMC free article] [PubMed] [Cross Ref]
17. Kwon HY, Eum WS, Jang HW, et al. Transduction of Cu, Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells. FEBS Lett. 2000;485:163–167. doi: 10.1016/S0014-5793(00)02215-8. [PubMed] [Cross Ref]
18. Venugopal R, Jaiswal AK. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene. 1998;17:3145–3156. doi: 10.1038/sj.onc.1202237. [PubMed] [Cross Ref]
19. Gang GT, Hwang JH, Kim YH, et al. Protection of NAD(P)H:quinone oxidoreductase 1 against renal ischemia/reperfusion injury in mice. Free Radic Biol Med. 2014;67:139–149. doi: 10.1016/j.freeradbiomed.2013.10.817. [PubMed] [Cross Ref]
20. Hou ST, MacManus JP. Molecular mechanisms of cerebral ischemia-induced neuronal death. Int Rev Cytol. 2002;221:93–148. doi: 10.1016/S0074-7696(02)21011-6. [PubMed] [Cross Ref]
21. Frantseva MV, Carlen PL, Perez Velazquez JL. Dynamics of intracellular calcium and free radical production during ischemia in pyramidal neurons. Free Radic Biol Med. 2001;31:1216–1227. doi: 10.1016/S0891-5849(01)00705-5. [PubMed] [Cross Ref]
22. Siegel D, Gustafson DL, Dehn DL, et al. NAD(P)H: quinone oxidoreductase1: role as a superoxide scavenger. Mol Pharmacol. 2004;65:1238–1247. doi: 10.1124/mol.65.5.1238. [PubMed] [Cross Ref]
23. Kim YH, Hwang JH, Noh JR, et al. Prevention of salt-induced renal injury by activation of NAD(P)H: quinone oxidoreductase1, associated with NADPH oxidase. Free Radic Biol Med. 2012;52:880–888. doi: 10.1016/j.freeradbiomed.2011.12.007. [PubMed] [Cross Ref]
24. Gang GT, Kim YH, Noh JR, et al. Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity. Toxicol Lett. 2013;221:165–175. doi: 10.1016/j.toxlet.2013.06.239. [PubMed] [Cross Ref]
25. Philip L, Shivakumar K. cIAP-2 protects cardiac fibroblasts from oxidative damage: An obligate regulatory role for ERK1/2 MAPK and NF-κB. J Mol Cell Cardiol. 2013;62:217–226. doi: 10.1016/j.yjmcc.2013.06.009. [PubMed] [Cross Ref]
26. Crossthwaite AJ, Hasan S, Williams RJ. Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurons: dependence on Ca2+ and PI3-kinase. J Neurochem. 2002;80:24–35. doi: 10.1046/j.0022-3042.2001.00637.x. [PubMed] [Cross Ref]
27. Park JS, Lee YY, Kim J, Seo H, Kim HS. β-Lapachone increase phase II antioxidant enzyme expression via AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes. Free Radic Biol Med. 2016;97:168–178. doi: 10.1016/j.freeradbiomed.2016.05.024. [PubMed] [Cross Ref]
28. Eichhorn JM, Alford SE, Sakurikar N, Chambers TC. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Exp Cell Res. 2014;322:415–424. doi: 10.1016/j.yexcr.2014.02.010. [PMC free article] [PubMed] [Cross Ref]
29. Park C, Choi YW, Hyun SK, et al. Induction of G1 arrest and apoptosis by schisandrin C isolated from Schizandra chinensis Baill in human leukemia U937 cells. Int J Mol Med. 2009;24:495–502. [PubMed]
30. Kato H, Tanaka S, Oikawa T, Koike T, Takahashi A, Itoyama Y. Expression of microglial response factor-1 in microglia and macrophages following cerebral ischemia in the rat. Brain Res. 2000;882:206–211. doi: 10.1016/S0006-8993(00)02811-0. [PubMed] [Cross Ref]
31. Cheung WM, Wang CK, Kuo JS, Lin TN. Changes in the level of glial fibrillary acidic protein (GFAP) after mild and severe focal cerebral ischemia. Chin J Physiol. 1999;42:227–235. [PubMed]
32. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [PubMed] [Cross Ref]
33. Ju SM, Youn GS, Cho YS, Choi SY, Park J. Celastrol ameliorates cytokine toxicity and pro-inflammatory immune responses by suppressing NF-κB activation in RINm5F beta cells. BMB Rep. 2015;48:172–177. doi: 10.5483/BMBRep.2015.48.3.147. [PMC free article] [PubMed] [Cross Ref]
34. Seo WY, Youn GS, Choi SY, Park J. Butein, a tetrahydroxychalcone, suppresses pro-inflammatory responses in HaCaT keratinocytes. BMB Rep. 2015;48:495–500. doi: 10.5483/BMBRep.2015.48.9.259. [PMC free article] [PubMed] [Cross Ref]

Articles from BMB Reports are provided here courtesy of Korean Society for Biochemistry and Molecular Biology